Event

FDA-approved therapies are now available for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and are currently being studied in other fibrotic diseases. We are now seeing several clinical trials in fibrosis based on novel rationales or employ innovative outcome measures. This session is designed to introduce some of these novel studies and to introduce the audience to adaptive clinical trial design, which is currently being studied in breast cancer. This design may help leverage the enormous amount of genomic data in pulmonary fibrosis to personalize therapy for patients.